Influence of physical factors on tablet splitting, weight and content uniformity of atenolol tablets

다국어 초록 (Multilingual Abstract)

Tablet splitting is widely practiced worldwide.
Several studies have considered weight variation of split tablets as a mean of estimating drug content uniformity but the analysis of their drug content and physical factors that may affect splitting are limited. The aim of this study is to evaluate the impact of manufacturing parameters and splitting on content and weight uniformity of atenolol tablets. Atenolol tablets (100 and 50 mg) were prepared under the same manufacturing conditions and using the same excipients. The obtained tablets were checked for hardness, weight, and disintegration. The weight and the content of the two strength atenolol tablets after splitting into two halves were evaluated. Atenolol tablets (100 mg)showed higher values of hardness, disintegration time and diameter than atenolol tablets (50 mg). Atenolol tablets (100 mg) passed both weight and content uniformity while atenolol tablets (50 mg) failed these tests. Half tablet weight appears to be directly correlated with its drug content. Manufacturers should investigate physical factors such as tablet hardness, diameter, and disintegration time that may play an important role in achieving both weight and content uniformity in the resultant tablet halves.

참고문헌 (Reference)

1 Zaid AN, "Weight uniformity ofscored tablet halves manufactured by Palestinian pharmaceuticalcompanies" 14 : 257-260, 2010

2 Polli JE, "Weight uniformity of split tabletsrequired by a Veterans Affairs policy" 9 : 401-407, 2003

3 Cook TJ, "Variability in tablet fragment weights when splitting unscoredcyclobenzaprine 10 mg tablets" 44 : 583-586, 2004

4 Katori N, "The study of the applicabilityof content uniformity and weight variation test- the state ofcommercial tablets and capsules in Japan" 49 : 1412-1419, 2001

5 United States Pharmacopeial Convention, "The UnitedStates Pharmacopeia, 29th Rev., and the National Formulary,24th edn" Rockville 212-, 2005

6 European Pharmacopoeia, "Suppl 6.4, Council of Europe;European Directorate for the Quality of Medicine"

7 European Pharmacopoeia, "Suppl 4.1, Council of Europe;European Directorate for the Quality of Medicine"

8 Fawell NG, "Relationship betweentablet splitting and compliance, drug acquisition cost, and patientacceptance" 56 : 2542-2545, 1999

9 Green G, "Pharmacopeial standardsfor the subdivision characteristics of scored tablets" 35 : 1598-1603, 2009

10 Kristensen HG, "Massuniformity of tablets broken by hand" 7 : 298-302, 1995

11 Teng J, "Lack of medicationdose uniformity in commonly split tablets" 42 : 195-199, 2002

12 Vranic´ E, "Influence of tablet splitting on contentuniformity of lisinopril/hydrochlorthiazide tablets" 7 : 328-334, 2007

13 Rindone JP, "Evaluation of tablet-splitting in patients takinglisinopril for hypertension" 7 : 22-24, 2000

14 Gee M, "Effects of a tabletsplittingprogram in patients taking HMG-Co A reductaseinhibitors: analysis of clinical effects, patient satisfaction,compliance, and cost avoidance" 8 : 453-458, 2002

15 Duncan MC, "Effect of tablet splittingon serum cholesterol concentrations" 36 : 205-209, 2002

16 Emilien G, "Current therapeutic uses andpotential of beta-adrenoceptor agonists and antagonists" 53 : 389-404, 1998

17 Abdel Naser Zaid, "Compliance of Scored Tablet Halves Produced by Palestinian Pharmaceutical Companies with the New European Pharmacopoeia Requirements" 대한약학회 34 (34): 1183-1189, 2011

18 Van Santen E, "Breaking of scoredtablets: a review" 53 : 139-145, 2002

19 Hill SW, "Analysis of drugcontent and weight uniformity for half-tablets of 6 commonlysplit medications" 15 : 253-261, 2009